New York, NY (PRWEB) March 20, 2014
The birth control safety advocates at DrugRisk.com have added new information to the site for patients who used the contraceptives Yaz or Yasmin. Recent court records show the number of pending lawsuits alleging the drugs caused side effects like blood clots has fallen for March*.
DrugRisk was created to give those patients taking popular prescription drugs the latest product recalls, safety alerts, research and litigation news. Visitors can recognize potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
The birth control center has added health warnings from experts such as the FDA** and British Medical Journal*** that oral contraceptives like Yaz and Yasmin containing drospirenone can increase the risk of blood clots. The U.K.’s Medicines and Healthcare Products Regulatory Agency also recently warned pills like Yasmin can double the risk of blood clots****.
Due to the number of patients who have filed a Yaz lawsuit alleging side effects, cases have been consolidated in a special federal court (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).
Now, DrugRisk has learned the latest report from the Judicial Panel on Multidistrict Litigation shows the number of claims pending has fallen more than 1% in less than a month, from 9,687 in February to 9,550 on March 13th*.
This comes after Bayer reported spending $1.69 billion so far to settle around 8,250 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)*****.
Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to visit DrugRisk or speak with a lawyer about their legal options. However, DrugRisk only recommends lawyers who have settled hundreds of Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*JPML, 3/13/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-March-13-2014.pdf
**FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
***BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
****British Journal of Family Medicine, Feb 2014; bjfm.co.uk/content/article.aspx?id=25769806997
*****Bayer Annual Report, Notes to Consolidated Financial Statement, Legal Risks, 2/28/14; annualreport2013.bayer.com/en/legal-risks.aspx